Ivabradine and AF: Coincidence, Correlation or a New Treatment?

Area of Science:

• Cardiology
• Pharmacology
• Electrophysiology

Background:

• Ivabradine is a selective heart rate-lowering agent targeting the If current.
• Approved for stable angina and heart failure (HF), it is frequently used in patients with comorbid atrial fibrillation (AF).
• Existing research presents mixed findings on ivabradine's efficacy and safety in AF management.

Purpose of the Study:

• To review current evidence on the relationship between ivabradine and atrial fibrillation (AF).
• To evaluate the potential role of ivabradine in AF treatment and sinus rhythm maintenance.
• To address the contradictory data regarding new-onset AF in patients taking ivabradine.

Main Methods:

• Review of recent scientific literature and clinical trial data.
• Analysis of experimental findings and clinical practice observations.
• Synthesis of diverse data concerning ivabradine and AF incidence.

Main Results:

• Experimental and limited clinical data suggest potential benefits of ivabradine for heart rate control in AF.
• Contradictory clinical practice data indicate an increased incidence of new-onset AF among ivabradine users.
• The evidence regarding ivabradine's role in AF treatment remains diverse and debated.

Conclusions:

• The role of ivabradine in the treatment of atrial fibrillation is complex and warrants further investigation.
• Clinical practice observations suggest a potential risk of new-onset AF with ivabradine, contrasting with some trial data.
• Further research is needed to clarify the net benefit and risks of ivabradine in patients with or at risk for AF.